Dogwood Therapeutics, Inc. (DWTX) Investor Relations Documents
Dogwood Therapeutics, Inc. (DWTX) investor relations documents from the company's IR site: 3 presentations, 17 press releases; latest deck 2026-08-03. Read in-app with summaries. First-party data.
Presentation: Dogwood Therapeutics is developing non-opioid pain medicines, with Halneuron for chemotherapy-induced neuropathy (CINP) expected to report Phase 2b data in Fall 2026.
Investor relations documents — source: company IR site| Published | Type | Document |
|---|
| 2026-08-17 | Press release | Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on Se |
| 2026-08-03 | Presentation | Presentation |
| 2026-07-20 | Press release | Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data E |
| 2026-06-30 | Press release | Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board |
| 2026-05-18 | Press release | Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Exten |
| 2026-05-14 | Press release | Dogwood Therapeutics Announces First Quarter 2026 Financial Results |
| 2026-05-14 | Press release | PDF |
| 2026-05-13 | Presentation | Corporate Presentation |
| 2026-05-07 | Press release | Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 |
| 2026-05-07 | Press release | Download as PDF |
| 2026-04-23 | Press release | Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potent |
| 2026-04-15 | Press release | Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemothe |
| 2026-03-18 | Press release | Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results |
| 2026-02-02 | Press release | Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2 |
| 2026-01-12 | Press release | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Developmen |
| 2025-09-29 | Presentation | https://d1io3yog0oux5.cloudfront.net/_15c7a6446d72696d589af450b695d8a9/dwtx/db/858/7593/pdf/Investor+Meeting+Presentation+Sept+29+2025.pdf |
| 2023-09-12 | Press release | Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023 |
| 2023-02-13 | Press release | Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Cele |
| 2023-01-05 | Press release | Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program |
| 2022-03-08 | Press release | Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022 |
DWTX overview · DWTX earnings · DWTX financials · DWTX KPIs · DWTX ownership · DWTX peers · DWTX filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.